5 Top NASDAQ Biotech Stocks: Neurocrine Biosciences Gained 32.68 Percent

Here's a closer look at last week's top gainers.

commodities investing

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went down 1.12 percent over the last five trading days and ended the week at 3,009.35 points. The Index is up 8.53 percent year-to-date.

Last week Jason Napodano from BioNap announced the launch of his new research service, in which he uses his 5 C’s method to evaluate life science companies, we interviewed Napodano a while ago about this novel concept and what to look for in companies. The Trump administration once again raised the potential for a new vote on healthcare reform as his first 100-day mark in the White House gets closer. Late last week Fiercebiotech reported on XBiotech likely getting rejected by the European Medicines Agency.

Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

CytRx Corporation (NASDAQ:CYTR)

Rockwell Medical Inc (NASDAQ:RMTI)

ImmunoGen, Inc. (NASDAQ:IMGN)

NewLink Genetics Corp (NASDAQ:NLNK)

TearLab Corp (NASDAQ:TEAR)

CytRx Corporation

This specialty biopharmaceutical is targeting cancer therapies for patients with soft tissue sarcoma through aldoxorubicin. Last week the company revealed its lead candidate is closer to obtaining FDA approval while saying it is tentatively targeting Q4 to launch and NDA.

CytRx Corporation gained 40.82 percent last week to finish at $0.61 per share.

Rockwell Medical

Rockwell is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease. Their drug products include Triferic and Calcitriol. Last week the company announced the filing of definitive proxy materials with the SEC.

However, there has been no further recent news from the company to explain last week’s rise in share price.

Rockwell Medical gained 33.28 percent last week to finish at $8.09 per share.

ImmunoGen

This clinical-stage biotechnology uses its antibody-drug conjugate technology to develop cancer therapies. Late last week the company announced a conference call for May 5, to discuss its upcoming Q1 2017 financial results.

According to The Motley Fool “an analyst at Leerink upgraded the biotech to outperform and slapped an $8 price target on the stock,” causing the increase. However, there has been no further recent news from the company to explain last week’s rise in share price.

ImmunoGen gained 24.38 percent last week to finish at $4.03 per share.

NewLink Genetics

NewLink is a clinical-stage company working on immunotherapeutic products for cancer treatment. The company announced the presentation of new data at the American Society of Clinical Oncology Annual Meeting in Chicago.

However, there has been no further recent news from the company to explain last week’s rise in share price.

NewLink Genetics Corp gained 16.65 percent last week to finish at $18.08 per share.

TearLab

This in-vitro diagnostic company has commercialized tear testing platform for sensitive and specific biomarkers in eye care. The last news from the company came in March as their announced their financial results for 2016 and its fourth quarter. In it, they reported revenue totaling $28 million.

However, there has been no further recent news from the company to explain last week’s rise in share price.

TearLab Corp gained 12.26 percent last week to finish at $2.38 per share.

 

Don’t forget to follow @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went up 0.12 percent over the last four trading days and ended the week at 3,043.38 points. The Index is up 9.76 percent year-to-date.

Last week we interviewed the CEO of Propanc Biopharma about their cancer technology. We also reported on OncoMed stumble as its key cancer trial got pulled. STAT News published a lenghty report on the severe case of yellow fever in Brazil.

Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

  • Neurocrine Biosciences (NASDAQ:NBIX)
  • Novelion Therapeutics (NASDAQ:NVLN)
  • Akorn, Inc. (NASDAQ:AKRX)
  • Galectin Therapeutics Inc. (NASDAQ:GALT)
  • ZIOPHARM Oncology (NASDAQ:ZIOP)

Neurocrine Biosciences

Neurocrine received a boost thanks to the news that the FDA approved Ingrezza, the company’s drug for tardive dyskinesia which causes involuntary movements in the face. Neurocrine earned FDA approval without getting a black box warning on depression and suicide.

Neurocrine Biosciences gained 32.68 percent last week to finish at $53.39 per share.

Novelion Therapeutics

Novelion is a pharmaceutical company working on therapies for rare diseases. Recently the company presented new data on an open-label study for patients with partial lipodystrophy associated NASH, at the Annual Meeting of the Endocrine Society.

Novelion Therapeutics gained 31.03 percent last week to finish at $10.36 per share.

Akorn

Akorn makes it to the list of top gainers for two weeks in a row after talks about an acquisition from Fresenius Kabi, a subsidiary of Fresenius Medical Care (NYSE:FMS) have continued, with analysts even declaring it a potentially fairly positive move. All speculation still with no confirmation yet.

Akorn gained 28.55 percent last week to finish at $32.42 per share.

Galectin Therapeutics

Also repeating after being featured in last week’s roundup, Galectin seeks to create new therapies that will help patients with chronic liver, skin diseases, and cancer.

Last week the company indicated it received positivity from the FDA about its current Phase II trial of GR-MD-02 designed to treat patients with NASH cirrhosis.

Galectin Therapeutics gained 28.46 percent last week to finish at $3.16 per share.

ZIOPHARM Oncology

ZIOPHARM is focused on acquiring, developing and commercializing a portfolio of cancer therapies. Most recently, on April 3,  the company gave an update on its chimeric antigen receptor T cell therapy for cancer.

However, there has been no further recent news from the company to explain last week’s rise in share price.

ZIOPHARM Oncology gained 19.58 percent last week to finish at $7.33 per share.

 

Don’t forget to follow @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went down 0.95 percent over the last five trading days and ended the week at 3,073.92 points. The Index is up 9.63 percent year-to-date.

Last week the Investing News Network reported on the GOP and President Trump’s intentions to bring their health care bill back for a new vote. The potential nominee to head the FDA, Scott Gottlieb last week expressed his stance against anti-vaccine people. Last week GEN reported on a new discovery on sleep genes from scientists at Washington State University.

  • Innocoll Holdings (NASDAQ:INNL)
  • Galectin Therapeutics (NASDAQ:GALT)
  • Akorn (NASDAQ:AKRX)
  • Pluristem Therapeutics (NASDAQ:PSTI)
  • Paratek Pharmaceuticals (NASDAQ:PRTK)

Here’s a closer look at those companies.

Innocoll Holdings

Innocoll is a commercial-stage pharmaceutical and medical device company set to develop its biodegradable and bioresorbable products and product candidates. Last week the company announced an agreement for Gurnet Point L.P. to acquire them, for an approximate $209 million in aggregate.

Innocoll Holdings gained 87.05 percent last week to finish at $2.10 per share.

Galectin Therapeutics

This biotechnology company seeks to create new therapies for patients with chronic liver, skin diseases, and cancer. Most recently Galectin presented their financial results for 2016, where it posted a net loss of $22.4 million. However, there has been no further recent news from the company to explain last week’s rise in share price.

Galectin Therapeutics gained 24.78 percent last week to finish at $2.87 per share.

Akorn

Akorn is a specialty generic pharmaceutical company developing, manufactures and markets generic and branded prescription pharmaceuticals. Shares of the company rose after a Bloomberg report, indicating Frenius SE (ETR:FRE) is considering a bid for the company.

Akorn gained 23.63 percent last week to finish at $29.77 per share.

Pluristem Therapeutics

This clinical-stage biotherapy company uses placenta-based cell therapy product candidates to treat ischemic, inflammatory and hematologic conditions.

Most recently the company announced it was in late conversations with Sosei Corporate Venture Capital to commercialize Pluristem’s PLX-PAD cell therapy product in Japan. However, there has been no further recent news from the company to explain last week’s rise in share price.

Pluristem Therapeutics gained 19.51 percent last week to finish at $1.47 per share.

Paratek

Paratek is a pharmaceutical company working on antibacterial therapeutics attempting to target infectious diseases.

Last week the company announced positive results from a Phase 3 clinical study of Omadacycline.

Paratek Therapeutics gained 16.75 percent last week to finish at $22.48 per share.

 

Don’t forget to follow @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) went up 1.09 percent over the last five trading days and ended the week at 3,073.92 points. The Index is up 10.7 percent year-to-date.

Last week it was reported president Trump requested major cuts from medical research at NIH, this comes after he released a federal budget where he indicated cuts to the health agency. Blueprint Medicines is raising $150 million for their trials.

Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

  • Athersys (NASDAQ:ATHX)
  • Impax Laboratories (NASDAQ:IPXL)
  • Adaptimmune Therapeutics (NASDAQ:ADAP)
  • Sangamo Therapeutics (NASDAQ:SGMO)
  • Karyopharm Therapeutics (NASDAQ:KPTI)

Athersys

This clinical-stage biotechnology company is focused on developing therapies in the space of regenerative medicine. Recently the company announced it would be presenting a corporate overview at the annual Needham Healthcare conference.

However, there has been no further recent news from the company to explain last week’s rise in share price.

Athersys gained 50 percent over the five-day trading week and ended at $1.71 per share.

Impax Laboratories

Impax is a specialty pharmaceutical developing generic products and branded ones. Last week the company received a favorable ruling regarding the patent validity for their nasal spray Zomig.

Impax Laboratories gained 36.76 percent over the five-day trading week and ended at $12.65 per share.

Adaptimmune Therapeutics

Adaptimmune is working on T-cell therapy to treat cancer through the use of their proprietary platform SPEAR. Last week Adaptimmune sold 15,700,223 American depositary shares at a price to the public of $4.20 per ADS.

The company gained 28.74 percent over the five-day trading week and ended at $5.51 per share.

Sangamo Therapeutics

This clinical stage biotechnology company seeks new therapies through the use of gene editing technology. Recently the company announced it would be presenting new data on the first-seen reduction of tau mRNA in a mouse model of Alzheimer’s disease.

Sangamo Therapeutics gained 26.83 percent over the five-day trading week and ended at $5.20 per share.

Karyopharm Therapeutics

Karyopharm is a clinical-stage pharmaceutical developing a drug against cancer. Last week the FDA lifted a clinical hold on trials for selinexor, a tumor suppressor, and enabled patient enrollment.

Karyopharm Therapeutics gained 22.52 percent over the five-day trading week and ended at $12.84 per share.

 

Don’t forget to follow @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Related reading, previous gainers:

5 Top NASDAQ Biotech Stocks: Nektar Therapeutics Gained 44.71 Percent

5 Top NASDAQ Biotech Stocks: Aurinia Pharmaceuticals Gained 76.72 percent

5 Top NASDAQ Biotech Stocks: HTG Molecular Diagnostics Gains 128.46 Percent

5 Top NASDAQ Biotech Stocks: Zosano Pharma Up 160 Percent


 

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) was down 1.62 percent over the last five trading days and ended the week at 3,036.19 points. The Index is up 9.5 percent year-to-date.

Last week Republicans turned down President Trump and House Speaker Paul Ryan’s plan to repeal and replace Obamacare with a new health care bill. Ultragenyx Pharmaceutical failed a trial for a rare genetic disorder, sending its stock price down.

Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:

  • Nektar Therapeutics (NASDAQ:NKTR)
  • Idera Pharmaceuticals (NASDAQ:IDRA)
  • Ekso Bionics Holdings (NASDAQ:EKSO)
  • Pulmatrix (NASDAQ:PULM)
  • OraSure Technologies (NASDAQ:OSUR)

Nektar Therapeutics

This clinical-stage biopharmaceutical has a pipeline of products involved in treatment for areas like cancer, autoimmune diseases, and chronic pain. The company announced positive results from NKTR-181, an opioid analgesic set to be non-addictive.

Nektar Therapeutics gained 44.71 percent over the five-day trading week and ended at $22.42 per share.

Idera Pharmaceuticals

Idera seeks to treat cancers and rare diseases like melanoma and dermatomyositis. The company recently posted its fourth quarter and 2016 financial results, where it claimed they would be looking into researching the full potential of one of their lead products IMO-2125. However, there has been no further recent news from the company to explain last week’s rise in share price.

Idera Pharmaceuticals gained 20.39 percent over the five-day trading week and ended at $2.48 per share.

Ekso Bionics

This company develops robotic exoskeletons to help patients recovering from injuries by promoting mobility and help correct the posture of the user. Last week the company appointed a new board member a healthcare veteran Howard Palefsky. However, there has been no further recent news from the company to explain last week’s rise in share price.

Ekso Bionics gained 17.48 percent over the five-day trading week and ended at $3.84 per share.

Pulmatrix

This biotechnology company seeks to create therapies to treat chronic respiratory diseases. Last week the company received a patent in Europe for its iSPERSE inhaled drug technology.

Pulmatrix gained 14.56 percent over the five-day trading week and ended at $3.54 per share.

OraSure Technologies

OraSure is working on developing medical devices designed to detect or diagnose critical medical conditions. The company was listed in the S&P SmallCap 600 (INDEXSP:SP600) last week.

OraSure Technologies gained 11.69 percent over the five-day trading week and ended at $12.13 per share.

Don’t forget to follow @INN_LifeScience for real-time updates!

Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Related reading, previous gainers:

5 Top NASDAQ Biotech Stocks: Aurinia Pharmaceuticals Gained 76.72 percent

5 Top NASDAQ Biotech Stocks: HTG Molecular Diagnostics Gains 128.46 Percent

5 Top NASDAQ Biotech Stocks: Zosano Pharma Up 160 Percent

5 Top NASDAQ Biotech Stocks: EnteroMedics Takes the Lead

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.

Biotech

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply